Translocations or amplifications in addition to the genomic alterations by now current in the initial CLL, but lack the typical mutations observed in primary DLBCL indicating they may correspond to a distinct biological class. . intolerance). Ibrutinib is the current gold standard therapy for patients with relapsed/refractory condition, according to https://paxtonehhfc.designertoblog.com/64387036/fascination-about-mbl77